How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Vamorolone for treating Duchenne muscular dystrophy in people 4 years and over

Closed for comments This consultation ended on at   Request commenting lead permission

Marketing authorisation indication

2.1

Vamorolone (Agamree, Santhera) is indicated for 'for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older'.

Price

2.3

The anticipated list price of vamorolone is £4,585.87 per 100 ml of a 40 mg/ml oral suspension (excluding VAT; company submission).

2.4

The company has a commercial arrangement, which would have applied if vamorolone had been recommended.